Cajundome in Louisiana to be renamed during Mardi Gras thanks to donation to LLS
Lafayette, Louisiana's Cajundome, a 13,500 seat multi-purpose arena that is normally home to the University of Louisiana at Lafayette's Ragin' Cajuns basketball teams and the Louisiana high school basketball state championship, will have a temporary new name during Mardi Gras, and the Leukemia & Lymphoma Society will be a beneficiary.
The fundraising efforts of Father Bryce Sibley with Our Lady of Wisdom Church and Catholic Student Center, along with his Ragin' Cajun Catholics Organization amounted to a donation of $2,651.00, all of which will go to the Leukemia & Lymphoma Society, specifically towards patient financial assistance in the state of Louisiana.
The donation also lets Father Bryce and his fundraisers to rename the Cajundome for a week. Thus during the week of Feb 17-21 2012, the dome will be renamed the "Ragin' Cajun Catholic Dome."
Source: KFLY.com
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
